Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia

Clara Deambrogi, Lorenzo De Paoli, Marco Fangazio, Stefania Cresta, Silvia Rasi, Valeria Spina, Valter Gattei, Gianluca Gaidano, Davide Rossi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The genetic profile of chronic lymphocytic leukemia (CLL) is characterized by a pool of recurrent lesions, including trisomy 12, deletions of 13q14, 11q22-q23, 17p13, and 6q21, and t(14)(q32) translocations [1]. The aforementioned lesions can be detected by FISH and may harbor prognostic information [1]. Array-based comparative genomic hybridization (aCGH) has identified gain of multiple regions on the short arm of chromosome 2 as a recurrent CLL lesion, that contain the REL, BCL11A, and MYCN proto-oncogenes that are involved in hematologic malignancies [2-5]. The exact prevalence of REL, BCL11A, and MYCN gains at the time of CLL diagnosis is currently unknown in consecutive series of the disease. Moreover, some studies indicate that 2p gains as a whole may herald progressive and/or poor risk disease, yet the prognostic contribution of the individual genes included in the amplicon, i.e., REL, BCL11A, and MYCN, remains undefined [4-6]. The aim of this study was twofold: (i) characterize the prevalence of REL, BCL11A, and MYCN gains in a consecutive CLL series at the time of diagnosis; (ii) define the prognostic relevance of REL, BCL11A, and MYCN gains in CLL.

Original languageEnglish
Pages (from-to)541-544
Number of pages4
JournalAmerican Journal of Hematology
Volume85
Issue number7
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Proto-Oncogenes
B-Cell Chronic Lymphocytic Leukemia
Comparative Genomic Hybridization
Chromosomes, Human, Pair 2
Trisomy
Hematologic Neoplasms
Genes

ASJC Scopus subject areas

  • Hematology

Cite this

Deambrogi, C., De Paoli, L., Fangazio, M., Cresta, S., Rasi, S., Spina, V., ... Rossi, D. (2010). Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia. American Journal of Hematology, 85(7), 541-544. https://doi.org/10.1002/ajh.21742

Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia. / Deambrogi, Clara; De Paoli, Lorenzo; Fangazio, Marco; Cresta, Stefania; Rasi, Silvia; Spina, Valeria; Gattei, Valter; Gaidano, Gianluca; Rossi, Davide.

In: American Journal of Hematology, Vol. 85, No. 7, 07.2010, p. 541-544.

Research output: Contribution to journalArticle

Deambrogi, C, De Paoli, L, Fangazio, M, Cresta, S, Rasi, S, Spina, V, Gattei, V, Gaidano, G & Rossi, D 2010, 'Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia', American Journal of Hematology, vol. 85, no. 7, pp. 541-544. https://doi.org/10.1002/ajh.21742
Deambrogi, Clara ; De Paoli, Lorenzo ; Fangazio, Marco ; Cresta, Stefania ; Rasi, Silvia ; Spina, Valeria ; Gattei, Valter ; Gaidano, Gianluca ; Rossi, Davide. / Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia. In: American Journal of Hematology. 2010 ; Vol. 85, No. 7. pp. 541-544.
@article{5c7a1b06efbb46c3a6b08a595f1b74a5,
title = "Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia",
abstract = "The genetic profile of chronic lymphocytic leukemia (CLL) is characterized by a pool of recurrent lesions, including trisomy 12, deletions of 13q14, 11q22-q23, 17p13, and 6q21, and t(14)(q32) translocations [1]. The aforementioned lesions can be detected by FISH and may harbor prognostic information [1]. Array-based comparative genomic hybridization (aCGH) has identified gain of multiple regions on the short arm of chromosome 2 as a recurrent CLL lesion, that contain the REL, BCL11A, and MYCN proto-oncogenes that are involved in hematologic malignancies [2-5]. The exact prevalence of REL, BCL11A, and MYCN gains at the time of CLL diagnosis is currently unknown in consecutive series of the disease. Moreover, some studies indicate that 2p gains as a whole may herald progressive and/or poor risk disease, yet the prognostic contribution of the individual genes included in the amplicon, i.e., REL, BCL11A, and MYCN, remains undefined [4-6]. The aim of this study was twofold: (i) characterize the prevalence of REL, BCL11A, and MYCN gains in a consecutive CLL series at the time of diagnosis; (ii) define the prognostic relevance of REL, BCL11A, and MYCN gains in CLL.",
author = "Clara Deambrogi and {De Paoli}, Lorenzo and Marco Fangazio and Stefania Cresta and Silvia Rasi and Valeria Spina and Valter Gattei and Gianluca Gaidano and Davide Rossi",
year = "2010",
month = "7",
doi = "10.1002/ajh.21742",
language = "English",
volume = "85",
pages = "541--544",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia

AU - Deambrogi, Clara

AU - De Paoli, Lorenzo

AU - Fangazio, Marco

AU - Cresta, Stefania

AU - Rasi, Silvia

AU - Spina, Valeria

AU - Gattei, Valter

AU - Gaidano, Gianluca

AU - Rossi, Davide

PY - 2010/7

Y1 - 2010/7

N2 - The genetic profile of chronic lymphocytic leukemia (CLL) is characterized by a pool of recurrent lesions, including trisomy 12, deletions of 13q14, 11q22-q23, 17p13, and 6q21, and t(14)(q32) translocations [1]. The aforementioned lesions can be detected by FISH and may harbor prognostic information [1]. Array-based comparative genomic hybridization (aCGH) has identified gain of multiple regions on the short arm of chromosome 2 as a recurrent CLL lesion, that contain the REL, BCL11A, and MYCN proto-oncogenes that are involved in hematologic malignancies [2-5]. The exact prevalence of REL, BCL11A, and MYCN gains at the time of CLL diagnosis is currently unknown in consecutive series of the disease. Moreover, some studies indicate that 2p gains as a whole may herald progressive and/or poor risk disease, yet the prognostic contribution of the individual genes included in the amplicon, i.e., REL, BCL11A, and MYCN, remains undefined [4-6]. The aim of this study was twofold: (i) characterize the prevalence of REL, BCL11A, and MYCN gains in a consecutive CLL series at the time of diagnosis; (ii) define the prognostic relevance of REL, BCL11A, and MYCN gains in CLL.

AB - The genetic profile of chronic lymphocytic leukemia (CLL) is characterized by a pool of recurrent lesions, including trisomy 12, deletions of 13q14, 11q22-q23, 17p13, and 6q21, and t(14)(q32) translocations [1]. The aforementioned lesions can be detected by FISH and may harbor prognostic information [1]. Array-based comparative genomic hybridization (aCGH) has identified gain of multiple regions on the short arm of chromosome 2 as a recurrent CLL lesion, that contain the REL, BCL11A, and MYCN proto-oncogenes that are involved in hematologic malignancies [2-5]. The exact prevalence of REL, BCL11A, and MYCN gains at the time of CLL diagnosis is currently unknown in consecutive series of the disease. Moreover, some studies indicate that 2p gains as a whole may herald progressive and/or poor risk disease, yet the prognostic contribution of the individual genes included in the amplicon, i.e., REL, BCL11A, and MYCN, remains undefined [4-6]. The aim of this study was twofold: (i) characterize the prevalence of REL, BCL11A, and MYCN gains in a consecutive CLL series at the time of diagnosis; (ii) define the prognostic relevance of REL, BCL11A, and MYCN gains in CLL.

UR - http://www.scopus.com/inward/record.url?scp=77954938896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954938896&partnerID=8YFLogxK

U2 - 10.1002/ajh.21742

DO - 10.1002/ajh.21742

M3 - Article

C2 - 20575024

AN - SCOPUS:77954938896

VL - 85

SP - 541

EP - 544

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -